Mucous Membrane Pemphigoid of the Anal Canal Resulting in Anal Stricture

Given the relative rare nature of MMP and the lack of literature specific to anorectal involvement, there may be a deficit of awareness in the medical community as well. [...]this case report is an opportunity for clinicians to highlight anorectal symptoms and treatment options for patients with a k...

Full description

Saved in:
Bibliographic Details
Published in:The American surgeon 2023-01, Vol.89 (1), p.157-159
Main Authors: Chapman, Brandon C., Goddard, Allison L., Schmitt, Colleen M., Mohr, Melinda R., Dozier, Tracy M., Nelson, Eric C.
Format: Article
Language:English
Subjects:
Airway management
Anal Canal
Anorectal
Antibodies
Anus
Anus Diseases
Autoantibodies
Biopsy
Blistering
Case reports
Colorectal surgery
Complications
Dermatology
Diagnosis
Differential diagnosis
Enzyme-linked immunosorbent assay
Esophagus
Health services
Humans
Immunofluorescence
Inflammation
Laminin
Malignancy
Medical screening
Medical treatment
Membranes
Morbidity
Mucosa
Mucous Membrane
Mucous membrane pemphigoid
Patients
Pemphigoid, Benign Mucous Membrane
Remission (Medicine)
Risk
Signs and symptoms
Skin
Skin diseases
Steroids
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Given the relative rare nature of MMP and the lack of literature specific to anorectal involvement, there may be a deficit of awareness in the medical community as well. [...]this case report is an opportunity for clinicians to highlight anorectal symptoms and treatment options for patients with a known diagnosis of pemphigoid to minimize morbidity. Additionally, a serum specimen for indirect immunofluorescence and enzyme-linked immunosorbent assay to detect circulating basement membrane zone antibodies may narrow the differential diagnosis and identify patients with autoantibodies to laminin 332 (previously known as laminin 5 and epiligrin) who are at higher risk for malignancy. 2 The primary goals of the treatment of MMP are to halt the progression of the disease, improve symptoms, and prevent adverse sequelae of chronic tissue inflammation and scarring. 2 In 2002, the First International Consensus on MMP, were published providing guidance on medical therapy for MMP. 3 Patients are categorized as high risk (ocular, genital, nasopharyngeal, esophageal, and laryngeal mucosa) or low risk (confined to the oral mucosa or oral mucosa and skin). [...]MMP is a chronic, blistering disease of the skin and mucous membranes.
ISSN:0003-1348
1555-9823
DOI:10.1177/0003134820952382